{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:26:26Z","timestamp":1790429186219,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA188354"],"award-info":[{"award-number":["R01 CA188354"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea","award":["1520250"],"award-info":[{"award-number":["1520250"]}]},{"name":"Creative-Pioneering Researchers Program through Seoul National University"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.trsl.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T16:39:47Z","timestamp":1522082387000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"special_numbering":"C","title":["Next-generation proteasome inhibitors for cancer therapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Ji Eun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yearin","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-869X","authenticated-orcid":false,"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Bo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.03.002_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","article-title":"Regulation of proteasome activity in health and disease","volume":"1843","author":"Schmidt","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2018.03.002_bib0015","doi-asserted-by":"crossref","first-page":"25637","DOI":"10.1074\/jbc.273.40.25637","article-title":"Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants","volume":"273","author":"Dick","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molcel.2008.03.004","article-title":"Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases","volume":"30","author":"Rabl","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.trsl.2018.03.002_bib0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","article-title":"Drugging the undruggables: exploring the ubiquitin system for drug development","volume":"26","author":"Huang","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2010.11.016","article-title":"Will the ubiquitin system furnish as many drug targets as protein kinases?","volume":"143","author":"Cohen","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2018.03.002_bib0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","article-title":"Molecular mechanisms in multiple myeloma drug resistance","volume":"69","author":"Nikesitch","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0045","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From bortezomib to other inhibitors of the proteasome and beyond","volume":"19","author":"Buac","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.trsl.2018.03.002_bib0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","article-title":"Positioning of proteasome inhibitors in therapy of solid malignancies","volume":"81","author":"Roeten","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0055","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1126\/science.275.5298.343","article-title":"An information-intensive approach to the molecular pharmacology of cancer","volume":"275","author":"Weinstein","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.trsl.2018.03.002_bib0065","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1959","article-title":"Success in translational research: lessons from the development of bortezomib","volume":"5","author":"Sanchez-Serrano","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2018.03.002_bib0075","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1021\/bi00497a001","article-title":"The multicatalytic proteinase complex, a major extralysosomal proteolytic system","volume":"29","author":"Orlowski","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.trsl.2018.03.002_bib0080","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/bi00154a014","article-title":"Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex","volume":"31","author":"Vinitsky","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.trsl.2018.03.002_bib0085","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJM199612193352507","article-title":"Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway","volume":"335","author":"Mitch","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.trsl.2018.03.002_bib0095","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"10.1016\/j.trsl.2018.03.002_bib0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.trsl.2018.03.002_bib0110","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2018.03.002_bib0120","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0125","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0130","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0135","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0140","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0145","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1535-7163.59.3.1","article-title":"The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts","volume":"3","author":"Nawrocki","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.trsl.2018.03.002_bib0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.trsl.2018.03.002_bib0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.trsl.2018.03.002_bib0165","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0175","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-14-2549","article-title":"CCR 20th anniversary commentary: In the beginning, there was PS-341","volume":"21","author":"Teicher","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0180","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0185","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/jm7010589","article-title":"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer","volume":"51","author":"Dorsey","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-015-9445-x","article-title":"Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice","volume":"42","author":"Zhang","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.trsl.2018.03.002_bib0195","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0200","first-page":"273","article-title":"Review. Clinical pharmacokinetics of bortezomib","volume":"21","author":"Leveque","year":"2007","journal-title":"In Vivo"},{"key":"10.1016\/j.trsl.2018.03.002_bib0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0210","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.trsl.2018.03.002_bib0215","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","article-title":"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites","volume":"33","author":"Pekol","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"pt 2","key":"10.1016\/j.trsl.2018.03.002_bib0220","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.clinthera.2009.11.012","article-title":"Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study","volume":"31","author":"Venkatakrishnan","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.trsl.2018.03.002_bib0225","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11594410-000000000-00000","article-title":"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma","volume":"50","author":"Hellmann","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trsl.2018.03.002_bib0230","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003088-200948030-00006","article-title":"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma","volume":"48","author":"Quinn","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trsl.2018.03.002_bib0235","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1179\/102453311X13025568941880","article-title":"Bortezomib in patients with renal impairment","volume":"16","author":"Kaygusuz","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.trsl.2018.03.002_bib0240","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1158\/1535-7163.MCT-09-0239","article-title":"The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models","volume":"8","author":"Williamson","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.trsl.2018.03.002_bib0245","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1021\/jm500352v","article-title":"Bilgicer B. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo","volume":"57","author":"Ashley","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2014.12.043","article-title":"Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy","volume":"208","author":"Shen","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.trsl.2018.03.002_bib0255","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.03.002_bib0260","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0265","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0270","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1182\/blood-2008-07-167767","article-title":"Many facets of bortezomib resistance\/susceptibility","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0275","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.trsl.2018.03.002_bib0280","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1476-4598-6-73","article-title":"The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells","volume":"6","author":"Voortman","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2018.03.002_bib0290","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0295","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0300","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0305","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0310","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.03.002_bib0315","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1074-5521(99)80128-8","article-title":"Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones","volume":"6","author":"Elofsson","year":"1999","journal-title":"Chem Biol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0320","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/S0960-894X(99)00612-5","article-title":"Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency","volume":"9","author":"Kim","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.trsl.2018.03.002_bib0325","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aaf8993","article-title":"The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design","volume":"353","author":"Schrader","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.trsl.2018.03.002_bib0330","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cbic.201600488","article-title":"High-resolution snapshots of proteasome inhibitors in action revise inhibition paradigms and inspire next-generation inhibitor design","volume":"17","author":"Carmony","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0335","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jphp.12072","article-title":"Carfilzomib: a novel agent for multiple myeloma","volume":"65","author":"Redic","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0340","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/febs.14016","article-title":"Activity-based probes for the multicatalytic proteasome","volume":"284","author":"Hewings","year":"2017","journal-title":"FEBS J"},{"key":"10.1016\/j.trsl.2018.03.002_bib0345","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trsl.2018.03.002_bib0350","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1021\/jm800548b","article-title":"Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides","volume":"51","author":"Manam","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0355","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2018.03.002_bib0360","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0365","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.trsl.2018.03.002_bib0370","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0375","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1200\/JCO.2013.52.3522","article-title":"Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"33","author":"Papadopoulos","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0380","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0385","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0390","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0395","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bcp.12542","article-title":"Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis","volume":"79","author":"Gupta","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0400","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40262-017-0526-4","article-title":"Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling","volume":"56","author":"Gupta","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trsl.2018.03.002_bib0405","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.leu.2404414","article-title":"Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells","volume":"21","author":"Kraus","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2018.03.002_bib0410","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/leu.2009.8","article-title":"Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells","volume":"23","author":"Ruckrich","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2018.03.002_bib0415","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1164\/rccm.201506-1122OC","article-title":"Impairment of immunoproteasome function by cigarette smoke and in chronic obstructive pulmonary disease","volume":"193","author":"Kammerl","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0420","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0425","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0430","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0435","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.trsl.2018.03.002_bib0440","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00280-017-3287-8","article-title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","volume":"79","author":"Quach","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0445","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0450","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.002_bib0455","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trsl.2018.03.002_bib0460","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcph.988","volume":"58","author":"Gupta","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0465","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bcp.12991","article-title":"Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment","volume":"82","author":"Gupta","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0470","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trsl.2018.03.002_bib0475","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0480","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trsl.2018.03.002_bib0485","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.V124.21.34.34","article-title":"Clinical profile of single-agent oprozomib in patients (Pts) with Multiple myeloma (MM): updated results from a multicenter, open-label, dose escalation phase 1b\/2 study","volume":"124","author":"Vij","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0490","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood.V128.22.2110.2110","article-title":"Final results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with hematologic malignancies","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0495","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","article-title":"A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.trsl.2018.03.002_bib0500","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/dmd.117.075226","article-title":"In vitro metabolism of oprozomib, an oral proteasome inhibitor: role of epoxide hydrolases and cytochrome P450s","volume":"45","author":"Wang","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.trsl.2018.03.002_bib0505","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Sanchez","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0510","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.leukres.2012.07.018","article-title":"CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma","volume":"36","author":"Sanchez","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0515","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Gallerani","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.trsl.2018.03.002_bib0520","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trsl.2018.03.002_bib0525","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.trsl.2018.03.002_bib0530","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1021\/ja058320b","article-title":"Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding","volume":"128","author":"Groll","year":"2006","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.trsl.2018.03.002_bib0535","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.trsl.2018.03.002_bib0540","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","article-title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model","volume":"149","author":"Singh","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0545","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","article-title":"The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia","volume":"5","author":"Ruiz","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.trsl.2018.03.002_bib0550","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","volume":"115","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0555","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","article-title":"Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.002_bib0560","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0565","first-page":"38","article-title":"[Changes in passive electric tissue properties of experimental tumors during carcinogenesis]","volume":"22","author":"Pliquett","year":"1989","journal-title":"Z Exp Chir Transplant Kunstliche Organe"},{"key":"10.1016\/j.trsl.2018.03.002_bib0570","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0575","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ccr.2013.07.008","article-title":"A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells","volume":"24","author":"Petrocca","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2018.03.002_bib0580","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.03.002_bib0585","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1","volume":"97","author":"Ling","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2018.03.002_bib0590","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2018.03.002_bib0595","doi-asserted-by":"crossref","first-page":"e27996","DOI":"10.1371\/journal.pone.0027996","article-title":"Molecular mechanisms of bortezomib resistant adenocarcinoma cells","volume":"6","author":"Suzuki","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.03.002_bib0600","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/jm300434z","article-title":"Molecular mechanisms of acquired proteasome inhibitor resistance","volume":"55","author":"Kale","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0605","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/mp300044b","article-title":"Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib","volume":"9","author":"Ao","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.trsl.2018.03.002_bib0610","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2009.123","article-title":"Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma","volume":"23","author":"Gutman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2018.03.002_bib0615","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2017.09.001","article-title":"Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma","volume":"182","author":"Ettari","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.trsl.2018.03.002_bib0620","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/1568009614666140723113139","article-title":"The immunoproteasome as a therapeutic target for hematological malignancies","volume":"14","author":"Miller","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.trsl.2018.03.002_bib0625","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbpa.2014.08.012","article-title":"Subunit specific inhibitors of proteasomes and their potential for immunomodulation","volume":"23","author":"Kisselev","year":"2014","journal-title":"Curr Opin Chem Biol"},{"issue":"4 suppl 92","key":"10.1016\/j.trsl.2018.03.002_bib0630","first-page":"S74","article-title":"The immunoproteasome: a novel drug target for autoimmune diseases","volume":"33","author":"Basler","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0635","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/med.21312","article-title":"Peptide-based proteasome inhibitors in anticancer drug design","volume":"34","author":"Micale","year":"2014","journal-title":"Med Res Rev"},{"key":"10.1016\/j.trsl.2018.03.002_bib0640","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem Biol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0645","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.4161\/cc.8.12.8798","article-title":"Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells","volume":"8","author":"Kazi","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trsl.2018.03.002_bib0650","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmc.2010.06.038","article-title":"Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors","volume":"18","author":"Lawrence","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0655","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1074\/jbc.M113.533950","article-title":"Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity","volume":"289","author":"Kazi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0660","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1021\/jm501344n","article-title":"Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening","volume":"58","author":"Miller","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0665","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/BJ20100383","article-title":"Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit","volume":"430","author":"Blackburn","year":"2010","journal-title":"Biochem J"},{"key":"10.1016\/j.trsl.2018.03.002_bib0670","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejmech.2017.01.034","article-title":"Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors","volume":"128","author":"Ge","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0675","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fchem.2014.00062","article-title":"Current challenges in peptide-based drug discovery","volume":"2","author":"Otvos","year":"2014","journal-title":"Front Chem"},{"key":"10.1016\/j.trsl.2018.03.002_bib0680","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12915-014-0094-0","article-title":"Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy","volume":"12","author":"Deshaies","year":"2014","journal-title":"BMC Biol"},{"key":"10.1016\/j.trsl.2018.03.002_bib0685","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrd4432","article-title":"SCF ubiquitin ligase-targeted therapies","volume":"13","author":"Skaar","year":"2014","journal-title":"Nat Rev Drug Discov"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T01:09:58Z","timestamp":1660698598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418300446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":136,"alternative-id":["S1931524418300446"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.03.002","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation proteasome inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}